arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

MiNK Therapeutics, Inc.

INKT
$10.90 ▼ -0.84 (-7.16%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
26 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
56
Health
Fair
Bullish
auto_awesome

Analytical Summary

MiNK Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $52.3M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 17.9%
FCF / Share $-0.36
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-2.74M
↑ +0.9%
FCF / Share Free cash flow per share
$-0.36
↓ -6.8%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Financial Health
12
Cash Quality
39

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters